Cigna Group
A Pennsylvania federal judge dismissed a lawsuit brought by Pennsylvania pharmacy customers against Cigna, Evernorth and Express Scripts. Plaintiffs alleged they were harmed after the companies labeled their community pharmacy as out-of-network. The decision was issued Thursday, according to Law360 Insurance Authority.
Jones Nicole S (See Remarks) sold 19,436 shares of Cigna Group (CI) at $276.27 ($5.37M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
Deutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.
Over the past 7 days, alphai's AI scored 11 news stories mentioning CI (Cigna Group). Coverage has skewed bearish: 1 bullish, 4 neutral, and 6 bearish.
Recent CI coverage spans financial news, market movers and insider activity.
In the last 30 days, CI insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($5.4M). The most active reporter was Jones Nicole S, See Remarks, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Dismissal reduces legal overhang tied to alleged out-of-network pharmacy designation in Pennsylvania.
This is an insider open-market sale under a pre-arranged 10b5-1 plan, which typically has limited signal value for near-term fundamentals.
Estimate-risk and business mix headwinds can reduce the stock’s valuation support.
Near-term trading focus shifts from headline earnings strength to regulatory risk around PBM operations and uncertainty from a business portfolio review.
The downgrade frames 2027 earnings risk as skewed to the downside, especially if EviCore or HIX are sold or wound down and GLP-1 coverage continues to erode.
alphai scores every news story that mentions CI with an AI model for sentiment and relevance, and aggregates insider trades from Cigna Group's SEC EDGAR Form 4 filings. Figures refresh continuously.
A Pennsylvania federal judge dismissed a lawsuit brought by Pennsylvania pharmacy customers against Cigna, Evernorth and Express Scripts. Plaintiffs alleged they were harmed after the companies labeled their community pharmacy as out-of-network. The decision was issued Thursday, according to Law360 Insurance Authority.
1 min readJones Nicole S (See Remarks) sold 19,436 shares of Cigna Group (CI) at $276.27 ($5.37M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
2 min readDeutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.
3 min readCigna Group (CI) reported Q2 2026 results: revenue of $71.67B and net income of $1.66B, plus additional $250M share repurchases. Despite the earnings growth, the stock fell about 9% as analysts cited PBM-related regulatory uncertainty and a business portfolio review. The article also references forecasts to 2029.
4 min readJefferies downgraded Cigna (CI) to Hold from Buy, citing mounting 2027 earnings headwinds and limited catalysts. It cut its price target to $307 from $336 and lowered its 2027 EPS estimate to $32.77, about 1% below consensus. Risks include uncertainty around EviCore and HIX, reduced GLP-1 coverage, and increased PBM regulatory scrutiny.
2 min readAfter Cigna’s Q2 update, Jefferies cut its rating to hold from buy and lowered its target to 307, citing limited near-term catalysts. Raymond James also reduced its rating and price objective. The article notes revenue growth but margin pressure in core pharmacy benefits, specialty care expansion, and an exit from some Obamacare plans. Insider and institutional activity data are also provided.
3 min readA roundup of Tuesday Wall Street analyst actions included Deutsche Bank upgrading Palantir to Buy and keeping a $200 target, and Wells Fargo initiating APi Group at Overweight with a $53 target. Other calls covered CoreWeave, Micron, Walmart, Nike, Apple, and SK Hynix, with multiple price targets and rating changes ahead of earnings for some names.
6 min readRaymond James downgraded Cigna (CI) to Outperform from Strong Buy and cut its price target to $320 from $350, citing attractive valuation but fewer near-term catalysts. It pointed to moderating growth and PBM headwinds. The firm cited Q2 adjusted EPS of $7.78, raised 2026 guidance to at least $30.45, and modeled $30.50 (2026), $33.50 (2027), $37.00 (2028).
4 min readGoldman Sachs raised its price target on Cigna Group (CI) to $352 from $340 while keeping a Buy rating, according to the firm. The article provides no additional earnings or financial figures, but the target change may influence investor expectations for CI’s valuation.
1 min readCigna reported Q2 2026 results showing profit divergence within Evernorth. Specialty and Care Services adjusted pre-tax operating income rose 22% to $1.05B on $26.97B revenue, while Pharmacy Benefit Services operating income fell 27% to $609M on $34.5B revenue. Total Evernorth adjusted revenue rose 6% to $61.47B, but operating income fell 2%. Cigna raised FY2026 adjusted EPS outlook to at least $30.45.
6 min read
